Journal
BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY
Volume 117, Issue 11, Pages 1399-1410Publisher
WILEY
DOI: 10.1111/j.1471-0528.2010.02689.x
Keywords
Highly active antiretroviral therapy; HIV; pregnancy; premature birth
Categories
Funding
- United Kingdom (UK) Medical Research Council (MRC) [G0501895]
- AVERT
- UK Department of Health
- Health Protection Agency [GHP/003/013/003]
- MRC Centre of Epidemiology for Child Health [G0400546]
- Department of Health's National Institute for Health Research Biomedical Research Centres
- US Centers for Disease Control and Prevention
- European Commission [PENTA/ECS 018865]
- Wellcome Trust [081082/A/06/Z]
- Progetto di Ricerca sull AIDS-Istituto Superiore di Sanita
- MRC
- MRC [G0400546, G0501895] Funding Source: UKRI
- Medical Research Council [G0501895, G0400546B, G0400546] Funding Source: researchfish
Ask authors/readers for more resources
Objective To investigate reported differences in the association between highly active antiretroviral therapy (HAART) in pregnancy and the risk of preterm delivery among HIV-infected women. Design Combined analysis of data from three observational studies. Setting USA and Europe. Population A total of 19 585 singleton infants born to HIV-infected women, 1990-2006. Methods Data from the Pediatric Spectrum of HIV Disease project (PSD), a US monitoring study, the European Collaborative Study (ECS), a consented cohort study, and the National Study of HIV in Pregnancy and Childhood (NSHPC), the United Kingdom and Ireland surveillance study. Main outcome measure Preterm delivery rate (< 37 weeks of gestation). Results Compared with monotherapy, HAART was associated with increased preterm delivery risk in the ECS (adjusted odds ratio [AOR] 2.40, 95% CI 1.49-3.86) and NSHPC (AOR 1.43, 95% CI 1.10-1.86), but not in the PSD (AOR 0.92, 95% CI 0.67-1.26), after adjusting for relevant covariates. Because of heterogeneity, data were not pooled for this comparison, but heterogeneity disappeared when HAART was compared with dual therapy (P = 0.26). In a pooled analysis, HAART was associated with 1.5-fold increased odds of preterm delivery compared with dual therapy (95% CI 1.19-1.87, P = 0.001), after adjusting for covariates. Conclusions Heterogeneity in the association between HAART and preterm delivery was not explained by study design, adjustment for confounders or a standard analytical approach, but may have been the result of substantial differences in populations and data collected. The pooled analysis comparing HAART with dual therapy showed an increased risk of preterm delivery associated with HAART.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available